Tags : m-Melanoma

Pharma

Clinigen Licenses Commercialization Rights for Proleukin from Novartis in the

Shots: Novartis to receive $210M as total deal value, including $120M upfront, $60M deferred payment for 12mos. and $30M milestone on sales of product. Clinigen to get commercialization rights for Novartis’ Proleukin in the US and WW license for Proleukin The focus of the agreement is to develop and commercialize Proleukin and strengthen Clinigen’s immune-oncology […]Read More